Meijer DK - Search Results

1

Delivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasone-anti-E-selectin immunoconjugate.

Asgeirsdóttir SA, Kok RJ, Everts M, Meijer DK, Molema G. Asgeirsdóttir SA, et al. Among authors: meijer dk. Biochem Pharmacol. 2003 May 15;65(10):1729-39. doi: 10.1016/s0006-2952(03)00122-9. Biochem Pharmacol. 2003. PMID: 12754109

2

Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate.

Everts M, Kok RJ, Asgeirsdóttir SA, Melgert BN, Moolenaar TJ, Koning GA, van Luyn MJ, Meijer DK, Molema G. Everts M, et al. Among authors: meijer dk. J Immunol. 2002 Jan 15;168(2):883-9. doi: 10.4049/jimmunol.168.2.883. J Immunol. 2002. PMID: 11777986

3

Cellular handling of a dexamethasone-anti-E-selectin immunoconjugate by activated endothelial cells: comparison with free dexamethasone.

Kok RJ, Everts M, Asgeirsdóttir SA, Meijer DK, Molema G. Kok RJ, et al. Among authors: meijer dk. Pharm Res. 2002 Nov;19(11):1730-5. doi: 10.1023/a:1020769716288. Pharm Res. 2002. PMID: 12458680

4

In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium.

Everts M, Koning GA, Kok RJ, Asgeirsdóttir SA, Vestweber D, Meijer DK, Storm G, Molema G. Everts M, et al. Among authors: meijer dk. Pharm Res. 2003 Jan;20(1):64-72. doi: 10.1023/a:1022298725165. Pharm Res. 2003. PMID: 12608538

5

Tumor vasculature targeted therapies: getting the players organized.

Molema G, Meijer DK, de Leij LF. Molema G, et al. Among authors: meijer dk. Biochem Pharmacol. 1998 Jun 15;55(12):1939-45. doi: 10.1016/s0006-2952(98)00011-2. Biochem Pharmacol. 1998. PMID: 9714313 Review.

6

Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure.

Kok RJ, Haverdings RF, Grijpstra F, Koiter J, Moolenaar F, de Zeeuw D, Meijer DK. Kok RJ, et al. Among authors: meijer dk. J Pharmacol Exp Ther. 2002 Jun;301(3):1139-43. doi: 10.1124/jpet.301.3.1139. J Pharmacol Exp Ther. 2002. PMID: 12023548

7

Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics.

Kok RJ, Schraa AJ, Bos EJ, Moorlag HE, Asgeirsdóttir SA, Everts M, Meijer DK, Molema G. Kok RJ, et al. Among authors: meijer dk. Bioconjug Chem. 2002 Jan-Feb;13(1):128-35. doi: 10.1021/bc015561+. Bioconjug Chem. 2002. PMID: 11792188

8

The influence of charge clustering on the anti-HIV-1 activity and in vivo distribution of negatively charged albumins.

Beljaars L, Floris R, Berkhout B, Smit C, Meijer DK, Molema G. Beljaars L, et al. Among authors: meijer dk. Biochem Pharmacol. 2002 May 1;63(9):1663-73. doi: 10.1016/s0006-2952(02)00912-7. Biochem Pharmacol. 2002. PMID: 12007569

9

Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting.

Schraa AJ, Kok RJ, Berendsen AD, Moorlag HE, Bos EJ, Meijer DK, de Leij LF, Molema G. Schraa AJ, et al. Among authors: meijer dk. J Control Release. 2002 Oct 4;83(2):241-51. doi: 10.1016/s0168-3659(02)00206-7. J Control Release. 2002. PMID: 12363450

10

Targeting of RGD-modified proteins to tumor vasculature: a pharmacokinetic and cellular distribution study.

Schraa AJ, Kok RJ, Moorlag HE, Bos EJ, Proost JH, Meijer DK, de Leij LF, Molema G. Schraa AJ, et al. Among authors: meijer dk. Int J Cancer. 2002 Dec 10;102(5):469-75. doi: 10.1002/ijc.10727. Int J Cancer. 2002. PMID: 12432548

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters